12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lyxumia lixisenatide regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA for Lyxumia lixisenatide from Sanofi to treat Type II diabetes....

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >